Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8964819 | Journal of Cystic Fibrosis | 2018 | 7 Pages |
Abstract
An ObsRO for children with CF ages 0-6 appears promising, while self-report may be more appropriate for children >Â 6Â years of age. Next steps for the 0-6Â year old instrument will be utilizing it as an exploratory endpoint in clinical trials to enable item reduction, scale development, and further reliability and validity testing. Ultimately, this ObsRO could be a promising endpoint for early intervention trials in young children with CF.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
T.C. Edwards, J. Emerson, A. Genatossio, S. McNamara, C. Goss, D.L. Patrick, F. Onchiri, M. Rosenfeld,